Corey J Langer, MD, FACP

Bennouna J et al. Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (bev) treatment beyond progression (PD) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) progressing after first-line bev chemotherapy (chemo). ASCO 2017;Abstract 9004.

Brueckl WM et al. Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Transl Lung Cancer Res 2021;10(7):3095-105. Abstract

Nakamura A et al. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTION study). Eur J Cancer 2023;184:62-75. Abstract

Shiono A et al. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. Thoracic Cancer 2019;10(4):775-81. Abstract

Karen Reckamp, MD, MS

He K et al. MRTX-500 phase 2 trial: Sitravatinib with nivolumab in patients with nonsquamous NSCLC progressing on or after checkpoint inhibitor therapy or chemotherapy. J Thorac Oncol 2023;19(7):P907-21. Abstract

Iyer S et al. Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617). AACR 2023;Abstract CT039.

Jacob Sands, MD

Goto Y et al. TROPION-Lung02: Datopotamab deruxtecan (dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (pt-CT) in advanced non-small cell lung cancer (aNSCLC). ASCO 2023;Abstract 9004.

Shimizu T et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol 2023; [Online ahead of print]. Abstract

Ticiana Leal, MD

Anadkat MJ et al. Expert guidance on prophylaxis and treatment of dermatologic adverse events with tumor treating fields (TTFields) therapy in the thoracic region. Front Oncol 2023;12:975473. Abstract

Leal T et al. Tumor treating field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study. ASCO 2023;Abstract LBA9005.

Villaruz LC. Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer. Cancer 2023;129(9):1319-50. Abstract